Sunquest Information Systems Partners with NGS Clinical Interpretation Leader, N-of-One

“Sunquest is pleased to announce our partnership with N-of-One, and CellNetix as our first customer ship (FCS) of our release featuring the N-of-One integration,” said Nabil Hafez, senior director of product management for Sunquest’s precision medicine solution, at the Association for Molecular Pathology Annual Meeting in Salt Lake City today. “Molecular and genetic testing is a big focus for cutting edge laboratories. Together we are working to bring the power of precision medicine to more clinicians treating patients with cancer. The latest release of Sunquest Mitogen is ideally suited to help laboratories start and scale their genetic testing services from the wet bench to the dry lab for hereditary conditions and somatic cancer.”

“The integration of N-of-One clinical interpretation solutions into Sunquest Mitogen software is a natural step,” said Chris Cournoyer, CEO of N-of-One. “Together we are expanding the reach of precision medicine by making it easy for hospital pathology labs, commercial laboratories, and precision medicine programs to obtain and deliver the highest-quality clinical interpretation of each patient’s cancer in the least amount of time.”

“Clinicians delivering precision medicine want more precise and tailored reports about a patient’s cancer – much more than detecting the genetic variants. Clinically actionable genetic reports provide the genetic variants and identify relevant treatments, pharmaceuticals, and clinical trials. CellNetix, Sunquest and N-of-One are working together to make precision medicine accessible to more clinicians, and in turn bring better care to more patients,” said Anna Berry, director of molecular pathology at CellNetix Pathology and Laboratories. CellNetix is an innovative, state-of-the-art anatomic pathology laboratory that provides cancer genomics testing through a custom-designed assay that incorporates the histopathology findings and informs clinical decision-making for both solid and hematologic malignancies.

A healthcare trend is the expansion of pathology laboratories into genetic interpretation services to meet a growing demand by clinicians and patients to support precision medicine while controlling healthcare costs. Precision medicine, also known as personalized medicine, customizes treatment, therapy and/or drugs to an individual patient based on genetics, often for cancer treatment. Sunquest Mitogen LIMS and Genetic Analysis supports this move of laboratories by tracking and reporting results for clinical specimens in laboratory workflows, and by improving the management of data associated with genetic testing, and supporting clinicians in generating laboratory reports that contain genetic test results as they start or grow molecular and genetic testing services.

Pathologist and oncologists will find the clear, concise genetic reports from Sunquest Mitogen Genetic Analysis provide clinically actionable value. N-of-One’s content enables creation of reports that include biomarker-driven therapies, clinical trials, other indicators, and genetic variant interpretation with the gene, variant, DNA change, effect and causative condition. Treatments are identified as actionable, applicable and contraindicated. Clinical trials are provided in a prioritized list, including the national clinical trial (NCT) identifier, phase of the trial, trial title and recruiting locations.

About N-of-One

N-of-One is the leader in identifying patient-specific therapeutic options for precision medicine in oncology by leveraging its proprietary knowledgebase and its team of oncologists and Ph.D. scientists to integrate molecular data from multiple tests. Using N-of-One solutions can standardize and accelerate genomic clinical interpretation and molecular decision support while saving time and money. N-of-One’s solutions have provided therapeutic options, including clinical trials, for tens of thousands of patient cases across hundreds of cancer types. N-of-One partners with leading hospital systems, cancer centers, and commercial labs around the world.

About CellNetix

CellNetix Pathology & Laboratories, LLC is a dynamic, rapidly growing, private pathology company headquartered in Seattle, Washington, serving hospitals and clinics throughout Washington, Oregon, Idaho and Alaska. CellNetix employs over 65 community-based pathologists and provides comprehensive sub-specialized anatomic pathology services at its central state-of-the-art laboratory in Seattle, with local laboratories throughout the Washington market and Alaska. Additionally, CellNetix provides medical directorships, and diagnostic services with comprehensive anatomic pathology services, offering a full-service menu, which includes Molecular pathology and Symgene™  a 79 gene Next Generation Sequencing assay for cancer. CellNetix performs diagnostics on over 230,000 surgical cases and more than 150,000 PAP smears annually.

About Sunquest Information Systems

Sunquest Information Systems Inc. provides diagnostic informatics solutions to more than 1,700 laboratories globally. Since 1979, Sunquest has helped laboratories and healthcare organizations across the world enhance efficiency, improve patient care, and optimize financial results. Sunquest’s solutions enable world-class lab capabilities, including multi-site, multi-disciplinary support for complex anatomic, molecular and genetic testing, and engagement with physicians and patients outside the hospitals at the point-of-care.

Headquartered in Tucson, AZ with offices in Boston, London, Dubai and Bangalore, Sunquest is a global leader in healthcare information technology. For more information, visit www.sunquestinfo.com/mitogen.